Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) traded down 3.5% during mid-day trading on Monday . The company traded as low as $7.71 and last traded at $7.75, with a volume of 74,221 shares changing hands. The stock had previously closed at $8.03.

Several equities research analysts have weighed in on ADAP shares. Leerink Swann reissued a “buy” rating on shares of Adaptimmune Therapeutics PLC – in a research report on Friday, April 8th. Zacks Investment Research raised shares of Adaptimmune Therapeutics PLC – from a “hold” rating to a “buy” rating and set a $9.75 price target for the company in a research report on Tuesday, July 12th. Six research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus price target of $15.94.

The company’s market capitalization is $518.85 million. The company has a 50 day moving average of $9.09 and a 200-day moving average of $8.78.

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) last released its quarterly earnings data on Thursday, May 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.03. Equities analysts predict that Adaptimmune Therapeutics PLC – will post ($1.12) earnings per share for the current year.

In related news, Director Charles Elliott Sigal acquired 45,000 shares of Adaptimmune Therapeutics PLC – stock in a transaction dated Wednesday, May 18th. The shares were purchased at an average price of $1.53 per share, for a total transaction of $68,850.00. Following the completion of the transaction, the director now directly owns 52,938 shares in the company, valued at approximately $80,995.14. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Orbimed Advisors Llc acquired 1,712,400 shares of Adaptimmune Therapeutics PLC – stock in a transaction dated Tuesday, May 24th. The shares were bought at an average price of $10.42 per share, for a total transaction of $17,843,208.00. The disclosure for this purchase can be found here.

Several large investors recently added to or reduced their stakes in the stock. Marshall Wace LLP bought a new stake in Adaptimmune Therapeutics PLC – during the fourth quarter valued at about $1,700,000. Tekla Capital Management LLC boosted its stake in Adaptimmune Therapeutics PLC – by 5.3% in the fourth quarter. Tekla Capital Management LLC now owns 296,934 shares of the company’s stock valued at $3,581,000 after buying an additional 15,000 shares during the last quarter. Finally, Jennison Associates LLC boosted its stake in Adaptimmune Therapeutics PLC – by 0.3% in the fourth quarter. Jennison Associates LLC now owns 486,948 shares of the company’s stock valued at $5,873,000 after buying an additional 1,547 shares during the last quarter.

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Company has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.